SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

BMC Pulm Med. 2014;14:81.

Significance of fractional exhaled nitric oxide in chronic eosinophilic pneumonia: a retrospective cohort study.

, , , , , , , ,

제1저자 박지영 · 교신저자 이춘택

소속 (1)
  1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Respiratory Center, Seoul National University Bundang Hospital, 173-82 Gumi-Ro, Bundang-Gu, Seongnam 463-707, Republic of Korea. ctlee@snu.ac.kr.

Abstract

BACKGROUND Chronic eosinophilic pneumonia (CEP) is characterized by chronic eosinophilic infiltration of the lung. It is dramatically responsive to corticosteroid treatment, but symptoms and radiopacities recur frequently after tapering or discontinuing the medication. Fractional exhaled nitric oxide (FeNO) is a well-known noninvasive marker of eosinophilic airway inflammation. The aim of this retrospective cohort study was to investigate the relationships of FeNO with peripheral eosinophilia and the clinical state of CEP and its validity for predicting exacerbation of CEP.

METHODS Standard clinical and laboratory parameters, peripheral eosinophil percentage and count, and FeNO level were measured in 18 patients with CEP at several assessment points over 1 year.

RESULTS FeNO level was positively correlated with peripheral eosinophil count (r = 0.341, P = 0.005) and percentage (r = 0.362, P = 0.003). The median (IQR) FeNO levels were 79 (41-88) and 35 (26-49) ppb in uncontrolled (13/74 measurements) and controlled (61/74 measurements) CEP, respectively (P = 0.010). The FeNO level of 66.0 ppb showed the largest area under the curve (0.835) for predicting exacerbation of CEP (sensitivity = 0.80, specificity = 0.84).

CONCLUSION FeNO may be useful for monitoring eosinophilic parenchymal inflammation and determining the appropriate corticosteroid dose in CEP.

Figures

Figure 1
Figure 1 Schematic of the study.
Figure 2
Figure 2 Relationship of FeNO level and peripheral eosinophilia in CEP. Scattergrams of FeNO level against peripheral eosinophil percentage (A) and count (B) as well as ΔFeNO against Δeosinophil percentage (C) and Δeosinophil count (D) at every assessment point are shown.
Figure 3
Figure 3 Parametric changes according to the clinical state of CEP. FeNO levels (A), peripheral eosinophil percentages (B), and peripheral eosinophil counts (C) in the controlled and uncontrolled states of CEP are shown.
Figure 4
Figure 4 FeNO levels during exacerbation of CEP and after corticosteroid treatment.
Figure 5
Figure 5 ROC curves of the studied parameters for predicting exacerbation of CEP. ROC curves of FeNO level (black solid line), ΔFeNO (gray solid line), peripheral eosinophil percentage (black dotted line), and peripheral eosinophil count (gray dashed-dotted line) are shown.

그림 출처: PubMed Central 공개 논문 (PMC4024211)

그 밖의 정보
출판 형태
Journal Article
저널
BMC pulmonary medicine · eISSN 1471-2466
전자 출판
2014-05-12
MeSH
Adrenal Cortex Hormones / therapeutic use · Adult · Biomarkers / analysis · Breath Tests / methods · Chronic Disease · Cohort Studies · Disease Progression · Exhalation · Female · Humans · Male · Middle Aged · Monitoring, Physiologic / methods · Nitric Oxide / analysis · Predictive Value of Tests · Pulmonary Eosinophilia / diagnosis / drug therapy · Retrospective Studies · Risk Assessment · Sensitivity and Specificity · Severity of Illness Index
Substances
Adrenal Cortex Hormones · Biomarkers · Nitric Oxide
참고문헌
27편